An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape 1 , 2 – 3 , have
activity against diverse sarbecoviruses 4 , 5 , 6 – 7 , and be highly protective through viral …

Efficient therapeutic options are needed to control the spread of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) that has caused more than 922,000 fatalities as of 13 …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

The spillovers of betacoronaviruses in humans and the emergence of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants highlight the need for broad coronavirus …

SARS-CoV-2 infection—which involves both cell attachment and membrane fusion—relies
on the angiotensin-converting enzyme 2 (ACE2) receptor, which is paradoxically found at low …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages carry
distinct spike mutations resulting in escape from antibodies induced by previous infection or …

The recent emergence of SARS-CoV-2 variants of concern 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 – 10
and the recurrent spillovers of coronaviruses 11 , 12 into the human population highlight the …

Cancer cells maintain a high glycolytic rate even in the presence of oxygen, a phenomenon
first described over 70 years ago and known historically as the Warburg effect. Fructose 2,6-…

Currently circulating SARS-CoV-2 variants have acquired convergent mutations at hot spots
in the receptor-binding domain 1 (RBD) of the spike protein. The effects of these mutations …

Understanding broadly neutralizing sarbecovirus antibody responses is key to developing
countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …